CUMULATIVE INDEX 1999

Volume 28

March	BILE SALTS: METABOLIC, PATHOLOGIC, AND THERAPEUTIC CONSIDERATIONS, pages 1–254
June	INFLAMMATORY BOWEL DISEASE, pages 255–523
September	PANCREAS UPDATE, pages 525–808
December	GASTROESOPHAGEAL REFLUX DISEASE, pages 809–1048

Note: Page numbers of article titles are in **boldface** type.

Aagenaes syndrome (Norwegian cholestasis), 43, 48
Ablative technology, for Barrett's esophagus, 920–921
Acid reflux, esophageal. See *Gastroesophageal reflux disease.*
Acini, anatomy of, 551–552
Acute Physiology and Chronic Health Evaluation (APACHE) system, in pancreatitis, 662–663
Acyl CoA–cholesterol ester transferase, in cholesterol homeostasis, 3
Adenocarcinoma, esophageal. See *Barrett's esophagus, adenocarcinoma development from.*
  pancreatic. See *Cancer, pancreatic.*
Adenosine triphosphate (ATP), in bile acid transport, 38–39, 166–168
Adhesion molecule inhibitors, in inflammatory bowel disease, 336–337
Age, Barrett's esophagus and, 922
  gallstone formation and, 86
  pancreatic cancer risk and, 679
Alagille syndrome, cholestasis in, 43, 46–47
Alcohol dehydrogenase, in bile acid synthesis, 6
Alcohol use, in Barrett's esophagus malignant degeneration, 928
  pancreatitis in, 572–574
    cancer risk in, 674–676
    pseudocyst formation in, 621
    treatment of, 690
Aldehyde dehydrogenase, in bile acid synthesis, 6
Alginic acid, in gastroesophageal reflux disease, 833
Aluminum hydroxide, in gastroesophageal reflux disease, 833, 897
American dilators, in peptic stricture, 886–887
Amikacin, in pancreatitis, in selective gut decontamination, 654
  prophylactic, 649, 651
5-Aminosalicylates, in inflammatory bowel disease, 297–300
  distal, 354
  ileal, 359
  in pediatric patients, 454–455
  in remission maintenance, 360
  left-sided, 355
  proctitis, 353–354
Amphotericin B, in selective gut decontamination, in pancreatitis, 654
Ampulla, stenosis of, pancreatitis in, 578
Amylase measurement, in pancreatic pseudocyst, 615–616, 622
Amylin, excess of, in pancreatic cancer, 711
Amyloidosis, in inflammatory bowel diseasc, 273, 450
Anesthetics, local, in inflammatory bowel disease, 336
Aneuploidy, DNA, in Barrett's esophagus malignant degeneration, 937
Ankylosing spondylitis, in inflammatory bowel disease, 268, 449
Ansa pancreatica, pancreatitis in, 577
Antacids, in gastroesophageal reflux disease, 832–833, 897, 990
  in pediatric patients, 963–964
Antibiotics, in collagenous colitis, 485
  in inflammatory bowel disease, 304–305, 324–325

Antibiotics *(Continued)*
in pediatric patients, 455
severe, 356
with peritonitis, 360
in pancreatitis, 606
prophylactic, **641–659**
in selective gut decontamination, 652–654
in severe acute cases, 648–654
intravenous, 648–652
need for, 642–643
recommendations for, 655–657
tissue penetrability and, 643, 645–648
Antigen-directed therapy, for inflammatory bowel disease, 323–325
Antihypertensive drugs, in Barrett's esophagus malignant degeneration, 932
Antineutrophil cytoplasmic antibodies, in inflammatory bowel disease, 285
Antinuclear antibodies, in primary sclerosing cholangitis, 495
Antinucleating agents, gallstone formation and, 84–85, 100–102
Antioxidant effect, of ursodeoxycholic acid, 203
Antireflux surgery. See *Fundoplication; Gastroesophageal reflux disease, treatment of, surgical.*
Antirefluxants, in gastroesophageal reflux disease, 832–833
Antithymocyte globulin, gastrointestinal complications of, 236–237
α_1-Antitrypsin deficiency, pancreatitis in, 585
APACHE (Acute Physiology and Chronic Health Evaluation) system, in pancreatitis, 662–663
APC gene, mutations of, in Barrett's esophagus malignant degeneration, 936
Apnea, obstructive, in gastroesophageal reflux disease, 949
apoE gene and product, gallstone formation and, 107–108
Apoproteins, in lipoprotein metabolism, 212–213
Appendix, inflammatory bowel disease pathogenesis and, 264–265
A_1achidonic acid metabolites, in inflammatory bowel disease, 337–338
Arginine-rich protein, 213
Arteriohepatic dysplasia (Alagille syndrome), cholestasis in, 43, 46–47
Arthritis, in collagenous colitis, 482
in inflammatory bowel disease, 267–268, 449
Ascites, pancreatic, 632
Aspergillosis, from immunosuppressive agents, 241
Aspiration, in gastroesophageal reflux disease, 950
Asthma, in gastroesophageal reflux disease, 813, 865–866, 949–950, 1009–1010
in peptic stricture, 880
Atherosclerosis, cholesterol homeostasis and, 1–3
ATP (adenosine triphosphate), in bile acid transport, 38–39, 166–168
Aureomycin, in selective gut decontamination, in pancreatitis, 652
Autoimmune disease, cholangitis, 174
pancreatitis in, 585
Autonomic nervous system, of pancreas, 553–554
Azathioprine, gastrointestinal complications of, 234–237
in inflammatory bowel disease, 301–303
cancer risk of, 472
refractory, 361
steroid-refractory, 356–357

B lymphocytes, in inflammatory bowel disease pathogenesis, 287–288
Bacitracin, in selective gut decontamination, in pancreatitis, 652
Backwash ileitis, in inflammatory bowel disease, 396
Bacteremia, in inflammatory bowel disease, in primary sclerosing cholangitis pathogenesis, 494
Barium studies, in esophageal peptic stricture, 880–881
in gastroesophageal reflux disease, 817–818, 956–957
preoperative, 993–994
in inflammatory bowel disease, 393–394, 396–409
Barrett's esophagus, **917–945**
adenocarcinoma development from, 917–920
incidence of, 917–918
lethality of, 919
risk factors for, 921–939
alcohol consumption, 928
demographic, 922–926
dietary, 930–932
dysplasia, 933–934
extent of disease, 928–930
genetic markers of, 934–939
medications, 932
obesity, 930–932
scleroderma, 932–933
symptoms, 921–922
tobacco use, 926–928
treatment of, 919
endoscopy in, 882

in pediatric patients, 951–952
peptic stricture in, 878
proton-pump inhibitors effects on, 852
treatment of, 920–921
surgical, 993, 1008–1009
Bed, elevating head, in gastroesophageal reflux disease, 832
Benign recurrent intrahepatic cholestasis, 43, 45–46
Bernstein test, in gastroesophageal reflux disease, 818, 960–961
Bethanechol, in gastroesophageal reflux disease, 837
Bile, composition of, 61
flow of. See also *Cholestasis.*
bile acid–independent, 30
regulation of, bile acids in, 30
ursodeoxycholic acid effects on, 198–200
gallstones and. See *Gallstones.*
lipids in. See *Biliary lipids; Cholesterol.*
supersaturation of, in gallstone formation, 100
vesicles in, 100
Bile acids. See also *Bile salts;* specific bile acids.
abnormalities of, **173–193**
in Blyler's disease, 188
in Caroli's syndrome, 188
in cystic fibrosis, 186
in primary biliary cirrhosis, 174–183, 203
in primary sclerosing cholangitis, 182, 184–187
conjugation of, absence of, 164
dehydroxylation of, 30
for gallstone dissolution, 138
hepatic clearance of, 31
hepatoprotective effects of, **195–209**
in primary biliary cirrhosis, 181–183, 203
homeostasis of, 79–80
in bile flow regulation, 30
in cholesterol 7α-hydroxylase feedback regulation, 10–12
metabolism of, inborn errors of, 17–18
primary, 28
synthesis of, 146
secondary, 28
secretion of, defects of, 69–70
ursodeoxycholic acid effects on, 198–200
synthesis of, **1–25**, 146–149
alternative (acidic) pathway of, 3–9
defects of, 162–164
cholesterol homeostasis and, 1–3
cholesterol 7α-hydroxylase in, 9–15
classic (neutral) pathway of, 3–9
defects in, 147, 150
conjugation absence, 164
7-dehydrocholesterol 7-reductase deficiency, 161–162
27-hydroxylase deficiency, 162
25-hydroxylase pathway, 161
7α-hydroxylation, 162–164
3β-hydroxysteroid dehydrogenase deficiency, 155–160
3-oxosteroid 5β-reductase deficiency, 151–155
peroxisomal, 164–165
types of, 147, 150–151
enzymes in, 146, 148–149
inborn errors of, **145–172**
overview of, 3–5
oxysterol 7α-hydroxylase in, 17
regulatory enzymes in, 9–17
side-chain oxidation and cleavage in, 6, 18
sterol 12α-hydroxylase in, 16–17
sterol 27-hydroxylase in, 15–16
toxicity of, in primary sclerosing cholangitis pathogenesis, 494
ursodeoxycholic acid effects on, 197–198, 201
transport of, **27–58**
as pharmaceutical target, 49
defects of. See also *Cholestasis.*
in intestine, 48–49
in liver, 42–48, 166–168
in enterohepatic circulation, 28–31
in intestine, 30–31, 39–42
defects of, 48–49
in liver, 31–39
canalicular, 28, 30, 38–39
defects of, 42–48, 166–168
facilitative, 34–35
intracellular, 36–37
passive diffusion in, 35
sodium-dependent transporters in, 33–34
Bile alcohols, excretion of, in primary biliary cirrhosis treatment, 179, 181
Bile ducts, injury of, in laparoscopic surgery, 125–128
nonsyndromic paucity of, 43, 47
stricture of, in primary sclerosing cholangitis, 503–504
Bile salts. See also *Bile acids.*
enterohepatic circulation of, lipoprotein metabolism and, **211–229**
in biliary lipid secretion, 60–61
in lipid aggregate formation, 76–78
sequestration of, for lipid-lowering, 223–224
Biliary bypass, laparoscopic, 129
Biliary lipids, **59–74**. See also *Cholesterol.*
aggregation of, 76–78
canalicular, composition of, 61, 63–64
secretion of, 65–67
composition of, 61, 63–64

Biliary lipids *(Continued)*
secretion of, 59–60
bile salts in, 60–61
canalicular, model for, 65–67
cholesterol component, 64–65
deficiencies of, 67–72
gallstone formation and, 78–80
importance of, 60
in familial intrahepatic cholestasis, 70
in *MDR3* gene product deficiency, 68
p-glycoproteins in, 61–63
ursodeoxycholic acid effects on, 198–200
types of, 76
Biliary pancreatitis. See *Gallstone pancreatitis.*
Biliary sludge, gallstone formation and, 84, 109
pancreatitis in, 580–582, 604
Biliary tract. See also *Bile ducts.*
disease of. See *Gallstones; Hepatobiliary disease; Primary sclerosing cholangitis.*
laparoscopic surgery on. See *Laparoscopic biliary surgery.*
Bilirubin, unconjugated, gallstone formation and, 78, 88–90, 105–107
Bilitec 2000 test, for nonacid gastroesophageal reflux disease, 854
Bismuth subsalicylate, in collagenous colitis, 485
in inflammatory bowel disease, 339
Black pigment gallstones, composition of, 76
formation of, 88, 105–107
Bloating, after antireflux surgery, 1000, 1014–1015
Blyler's disease and Blyler's syndrome, 43–45, 69–70, 166–168
cholestasis in, ursodeoxycholic acid for, 188
Borage oil, in inflammatory bowel disease, 435
Bougienage, in esophageal peptic stricture, 886–887
Bowel rest, in inflammatory bowel disease, 305
BRIC gene, in recurrent intrahepatic cholestasis, 46
Bronchitis, chronic, gastroesophageal reflux disease and, 867
Bronchospasm, in gastroesophageal reflux disease, 865–866, 949–950
Brooke ileostomy, in ulcerative colitis, 374–375
Brown pigment gallstones, composition of, 76
formation of, 89–91, 105–107
Budesonide, in inflammatory bowel disease, 301
in pediatric patients, 454–455
steroid-dependent, 358
Bypass, biliary, laparoscopic, 129
Bypass (diversion) colitis, 487–488

CA 19–9 tumor marker, for pancreatic cancer, 712–713
cag gene, of *Helicobacter pylori*, gastroesophageal reflux and, 976
Calcium, in gallstones, 101–102
pigment, 88–90, 105–106
Calcium carbonate, in gastroesophageal reflux disease, 833
Caloric requirements, in inflammatory bowel disease, 426
Canaliculi, bile acid transport in, 28, 30, 38–39
bile lipids of, 61, 63–67
Cancer, esophageal. See *Barrett's esophagus, adenocarcinoma development from.*
gallbladder, as gallstone complication, 135
laparoscopic surgery for, 125
in inflammatory bowel disease, 272, **459–477**
cholangiocarcinoma, 504–505
colorectal. See *Colorectal cancer, in inflammatory bowel disease.*
hematologic, 471–472
skin, 472–473
small intestinal, 472
laryngeal, in gastroesophageal reflux disease, 867–869
pancreatic, **709–722**
clinical features of, 710–712
diagnosis of, age at, 678
computed tomography in, 725, 727–729, 731, 733–735, 737
endoluminal ultrasonography in, 773, 776
endoscopic, 794–795
magnetic resonance imaging in, 740–742
positron emission tomography in, 743, 745
staging in, 713–716, 749–751
tumor markers in, 712–713
ultrasonography in, 747–753
endocrine cells in, 563
endocrine pancreatic disorders in, 562–563
endoscopic ultrasonography in, in fine-needle aspiration, 751–753
in staging, 749–751
endoscopy in, 794–796
epidemiology of, 709–710
genetic factors in, 710
pancreatitis in, 576
prognosis for, 719

risk factors for, **673–685**, 709–710
acute pancreatitis, 673–674
age, 679
chronic pancreatitis, 674–676
cystic fibrosis, 677–678
diabetes mellitus, 560–561, 681
genetic, 678, 682
hereditary pancreatitis, 527, 676–677
racial, 680–681
smoking, 679–680
tropical pancreatitis, 677
staging of, 713–716
treatment of, endoscopic, 796
medical, 718
radiation therapy in, 718–719
surgical, 716–718
Candidiasis, from immunosuppressive agents, 241
Caroli's syndrome, cholestasis in, ursodeoxycholic acid for, 188
Catheter, percutaneous, in pancreatic pseudocyst drainage, 626–627, 630
CD4 molecule, antibodies to, in inflammatory bowel disease treatment, 326
CDKN2/p16 gene, mutations of, in Barrett's esophagus malignant degeneration, 936–937
CDP571 monoclonal antibody, in inflammatory bowel disease, 306, 329
Cefotaxime, in pancreatitis, in selective gut decontamination, 654
prophylactic, 648–649, 656–657
Ceftazidime, prophylactic, in pancreatitis, 649, 656–657
Ceftriaxone, gallstone formation and, 109
Cefuroxime, prophylactic, in pancreatitis, 650–651, 655
Celiac disease, versus collagenous colitis, 481–482
Celiac plexus block, in pancreatic cancer, 718
Cell adhesion molecules, antibodies to, in inflammatory bowel disease, 337
Cephalosporins, prophylactic, in pancreatitis, 648–651, 654, 656–657
Cerebrohepatorenal (Zellweger's) syndrome, 164–165
Cerebrotendinous xanthomatosis, in bile acid synthesis defects, 18, 162
Chemotherapy, for pancreatic cancer, 718–719
Chenodeoxycholic acid, secretion of, in primary biliary cirrhosis treatment, 176–177
synthesis of, 3–9
therapeutic, in cerebrotendinous xanthomatosis, 162
in gallstone dissolution, 138
in 3β-hydroxysteroid dehydrogenase deficiency, 158–160
in Zellweger's syndrome, 165
Chest pain, in gastroesophageal reflux disease, 812, 863–864, 989
in peptic stricture, 880
Chloroquine, in inflammatory bowel disease, 340
Cholangiocarcinoma, in primary sclerosing cholangitis, 504–505
Cholangiography, in choledocholithiasis, 121
in iatrogenic biliary injury, 128
in primary sclerosing cholangitis, 498–499
Cholangiopancreatography, endoscopic retrograde. See *Endoscopic retrograde cholangiopancreatography.*
magnetic resonance, 742–743
Cholangitis, acute, laparoscopic surgery in, 123
autoimmune, 174
primary sclerosing. See *Primary sclerosing cholangitis.*
Cholecystectomy, after pancreatitis, 607
in gallstone diseases, 136–137
laparoscopic. See *Laparoscopic biliary surgery.*
pancreatitis after, 603
Cholecystitis, acute, laparoscopic surgery in, 119–120
in gallstone disease, 134
Cholecystokinin, in pancreatic secretion regulation, 555–556, 558–559
inhibition of, gallstone formation in, 103–104
Cholecystokinin-releasing peptide, in pancreatic secretion regulation, 556–557
Choledochojejunostomy, in pancreatic cancer, 717
Choledocholithiasis, in inflammatory bowel disease, 503
laparoscopic surgery in, 120–122
Choledochotomy, laparoscopic, 121–122
Cholelithiasis. See *Gallstones.*
Cholestasis, benign recurrent intrahepatic, 43, 45–46
bile acid hepatoprotection in, 197–201
familial intrahepatic, 42–48, 145–146
progressive, 43–45, 69–72, 166–168
in Byler's disease and Blyler's syndrome, 43–45, 69–70, 166–168, 188
in Caroli's syndrome, 188
in cystic fibrosis, 186
in giant cell hepatitis, 155–160
in 25-hydroxylase pathway defects, 161
in 7α-hydroxylation defects, 162–164
in 3β-hydroxysteroid dehydrogenase deficiency, 155–160
in inflammatory bowel disease, treatment of, 502

Cholestasis *(Continued)*
in 3-oxosteroid 5β-reductase deficiency, 151–155
in peroxisomal disorders, 164–165
in primary biliary cirrhosis, 174–182
in primary sclerosing cholangitis, 182, 184–187
in Zellweger's syndrome, 164–165
Native American, 43, 47–48
neonatal, severe, 151–155
Norwegian, 43, 48
pathology of, 196–197
Cholesterol, crystallization of, 84–85, 100–102
deficiency of, in 7-dehydrocholesterol 7-reductase deficiency, 161–162
degradation of, 78
homeostasis of, 1–3
gallstone formation and, 78–80, 88
hypersecretion of, gallstone formation and, 82–83
in bile acid synthesis, 1–3
in cholesterol 7α-hydroxylase feedback regulation, 12–13
in gallstones. See *Cholesterol gallstones.*
secretion of, into bile, 64–65
synthesis of, in gallbladder, 102–103
transport of, reverse, 8, 15, 219
Cholesterol ester transfer protein, in lipoprotein metabolism, 219–220
Cholesterol gallstones, composition of, 75–76
formation of, 80–88
age factors in, 86
cholesterol homeostasis and, 78–80
cholesterol hypersecretion and, 82–83
crystallization in, 84–85, 100–102
diet and, 87
drug-induced, 88, 108–109
estrogens and, 86
gallbladder role in, 83–84, 102–104
genetic factors in, 87–88, 107–108
hyperlipidemia and, 87
in obesity, 86
in pregnancy, 86
in spinal cord injury, 88
infections and, 85, 104–105
intestinal bile salt metabolism and, 84
intestinal hypomotility and, 87
lipid aggregates and, 76–78
metabolic factors in, 85–88
nucleation in, 84–85, 100–102
physical factors in, 84–85
rapid weight loss and, 86
vicious cycle of, 80, 82
Cholesterol 7α-hydroxylase, defects of, 162–164
gene for, manipulation of, 224
in bile acid synthesis, 4, 8–15
bile acid regulation of, 10–12
biology of, 9–10
cholesterol regulation of, 12–13
cytokine regulation of, 14
hormonal regulation of, 13–14
intestinal factor regulation of, 14
overexpression studies of, 14–15
Cholesteryl ester hydrolase, in cholesterol homeostasis, 3
Cholestyramine, bile salt enterohepatic circulation and, 223–224
in collagenous colitis, 485
in inflammatory bowel disease, in cholestasis, 502
in remission maintenance, 361
Cholic acid, secretion of, in primary biliary cirrhosis treatment, 176–178, 180–181, 183
synthesis of, 3–9
therapeutic, in 3-oxosteroid 5β-reductase deficiency, 154–155
in Zellweger's syndrome, 165
Chromosomal aberrations, in Barrett's esophagus malignant degeneration, 936–937
Chylomicrons, in lipoprotein metabolism, 214–215
Cimetidine, in gastroesophageal reflux disease, 834–835
in pediatric patients, 964
with otolaryngologic conditions, 868
Ciprofloxacin, in inflammatory bowel disease, 305, 325, 359
prophylactic, in pancreatitis, 648–649, 655–656
Cirrhosis, biliary. See *Primary biliary cirrhosis.*
Cisapride, in gastroesophageal reflux disease, 838–840, 849, 991
in pediatric patients, 962–963
refractory, 855–856
Clarithromycin, in inflammatory bowel disease, 325
Clindamycin, prophylactic, in pancreatitis, 656–657
CoA ligase, in bile acid synthesis, 6
Coagulation disorders, of inflammatory bowel disease, 450
Colectomy, in Crohn's disease, 386–388
in ulcerative colitis, in cancer prevention, 465
subtotal, 374–375
Colic, biliary, in gallstone disease, 135–136
Colistin, in selective gut decontamination, in pancreatitis, 654
Colitis, atypical, **479–490**
collagenous, 479–487
Crohn's, treatment of, 359, 386–388
differential diagnosis of, endoscopy in, 410–414
diversion, 487–488

from immunosuppressive agents, herpetic, 239
neutropenic, 242
lymphocytic, 481, 486–487
ulcerative. See *Ulcerative colitis.*
Collagenous colitis, 479–486
clinical features of, 482–483
diagnosis of, 483
histopathology of, 479–482
incidence of, 479
pathogenesis of, 483–484
pathophysiology of, 484
prognosis for, 485–486
treatment of, 484–485
versus lymphocytic colitis, 481, 486–487
Collis procedure, in gastroesophageal reflux disease, 1009, 1011
in peptic stricture, 887–888
in shortened esophagus, 1001
Colocolic fistula, in Crohn's disease, radiography of, 409
Colon, cancer of. See *Colorectal cancer.*
hemorrhage of, in inflammatory bowel disease, 266, 373, 497–498
obstruction of, in inflammatory bowel disease, 373
perforation of, in inflammatory bowel disease, 267, 373, 448–449
Colonoscopy, in inflammatory bowel disease, in cancer surveillance, 417, 465–468
in differential diagnosis, 410–414
in disease extent evaluation, 414–415
in pediatric patients, 452
in response to therapy evaluation, 416
preoperative, 416–417
recurrent, 416
Colorectal cancer, in inflammatory bowel disease, biology of, 459–460
in pediatric patients, 448
prevention of, 464–469, 471
risk for, 269, 274, 460–464, 469–471
surgical prophylaxis of, 372, 464–465
surveillance for, 417, 465–468
Colostomy, diversion colitis in, 487–488
Common channel theory, of gallstone pancreatitis, 602
Computed tomography, in inflammatory bowel disease, 394
of pancreas, 723–738
accuracy of, 729, 732
contrast agents for, 729, 736
in cancer, 714–715, 725, 727–729, 731, 733–735, 737
in insulinoma, 726
in pancreatitis, 663–664, 738
in pseudocyst, 622
normal, 724
technique for, 725, 729
Continent ileostomy, in ulcerative colitis, 375–376
Contrast agents, for pancreatic imaging, computed tomography, 729, 736
magnetic resonance imaging, 741
Copper deposition, in primary sclerosing cholangitis pathogenesis, 494–495, 500–501
Corticosteroids, gastrointestinal complications of, 235–237
in cholesterol 7α-hydroxylase feedback regulation, 13
in inflammatory bowel disease, 300–301
distal, 354
ileal, 359
in pediatric patients, 455
steroid-dependent, 357–358
intralesional, in esophageal peptic stricture, 886
Cortisol, in cholesterol 7α-hydroxylase feedback regulation, 13
Cough, in gastroesophageal reflux disease, 864–865, 1009–1010
in peptic stricture, 880
C-reactive protein, in pancreatitis staging, 663
inhibitors of, in pancreatitis, 593–598
Critical micellar concentration, of bile salt monomers, 76
Crohn's disease, cancer in, 272
hematologic, 471–472
prevention of, 471
risk for, 469–471
skin, 472–473
small intestinal, 472
clinical features of, in pediatric patients, 447
colorectal, treatment of, 359, 386–388
diagnosis of, in pediatric patients, 451–453
differential diagnosis of, in pediatric patients, 453
distribution of, radiography of, 394–395
endoscopy in. See *Endoscopy, in inflammatory bowel disease.*
epidemiology of, 255–260
in pediatric patients, 445–446
extraintestinal manifestations of, 271, 273–274
in pediatric patients, 449–450
fistula formation in, treatment of, 362–363, 408–409
gastroduodenal, treatment of, 358–359
gastrointestinal complications of, in pediatric patients, 447–449
genetic factors in, 260–262, 284–285
growth failure in, 451
hepatobiliary disease in. See *Hepatobiliary disease, in inflammatory bowel disease; Primary sclerosing cholangitis.*
heterogeneity of, 285
ileitis in, 359

Crohn's disease *(Continued)*
ileocolitis in, 359
in elderly persons, 276
in pediatric patients. See *Pediatric patients, inflammatory bowel disease in.*
natural history of, 270–275
nutrition in. See *Nutrition, in inflammatory bowel disease.*
oral, treatment of, 358
pathogenesis of, **283–296**
animal models of, 288–290
environmental factors in, 262–264, 284–285
genetic factors in, 260–262
theories on, 286–288
perianal, in pediatric patients, 449
treatment of, 363
peritonitis in, 360
quality of life in, 274–275
radiography in, barium enema in, 393–394
computed tomography in, 394
findings in, 403–409
in disease distribution, 394–396
peroral pneumocolon with small bowel enema in, 392–393
plain film in, 392
recurrent, 271–273
endoscopy of, 416
postoperative, 363–364
treatment of, 386
refractory, treatment of, 361–362
risk factors for, 260–265
severity of, 270–271
small bowel obstruction in, 360, 383–386
steroid-dependent, treatment of, 361–362
survival in, 274
treatment of, 358–364
adhesion molecule inhibitors in, 336–337
aminosalicylates in, 297–300
antibiotics in, 304–305, 324–325
antigen-directed, 323–325
biologic approaches to, 306–307
colitis, 359
corticosteroids in, 300–301
cytokines in, anti-inflammatory, 332–334
proinflammatory, 325–331
fistula formation, 362–363
gastroduodenal, 358–359
hyperbaric oxygen therapy in, 340
ileitis, 359
ileocolitis, 359
immunoglobulins in, 341
immunomodulators in, 301–304
immunosuppressive agents in, 306–307, 334, 455
immunotherapy in, 290–291
in pediatric patients, 453–456
in remission maintenance, 360–361
interferon-α in, 340
investigational therapies in, 306–307
medical, **297–321**
in pediatric patients, 455–456
neuroimmunomodulators in, 334–336
novel, **323–351**
nutritional therapy in. See *Nutrition, in inflammatory bowel disease.*
oral, 358
perianal, 363
peritonitis, 360
probiotics in, 325
recurrent postoperative, 363–364
refractory, 361–362
small bowel obstruction, 360
steroid-dependent, 361–362
supportive therapy in, 305–306
surgical, colorectal, 386–388
small intestinal, 383–386
versus collagenous colitis, 481
versus diversion colitis, 488
Cyclin, overexpression of, in Barrett's esophagus malignant degeneration, 937
Cyclophosphamide, gastrointestinal complications of, 235
Cyclosporine, gastrointestinal complications of, 234, 236–237
in inflammatory bowel disease, 303–304
refractory, 362
severe, 356
in primary biliary cirrhosis, 174
CYP7A. See *Cholesterol 7α-hydroxylase.*
CYP7B (oxysterol 7α-hydroxylase), in bile acid synthesis, 17
CYP12 (sterol 12α-hydroxylase), in bile acid synthesis, 16–17
CYP27 (sterol 27-hydroxylase), deficiency of, 18
in bile acid synthesis, 6, 15–16
Cyst(s), pancreatic. See also *Pseudocyst(s), pancreatic.*
differential diagnosis of, 617
endoluminal ultrasonography of, 776–777
endoscopic ultrasonography of, 754–755
pancreatitis in, 578
Cystic fibrosis, **543–550**
cholestasis in, ursodeoxycholic acid for, 186
cystic fibrosis transmembrane conductance regulator gene mutations in, 545–548
pancreatic function in, exocrine-endocrine relationships in, 563–565
insufficiency in, 543–544, 563–564
pancreatitis in, 584–585
cancer risk in, 677–678

pathogenesis of, 563–564
Cystic fibrosis transmembrane conductance regulator protein, action of, 544–545, 563–564
defects of, frequency of, 545–546
pancreatitis in, 546–548
Cystoduodenostomy, in pancreatic pseudocyst drainage, endoscopic, 627–628, 788–789
laparoscopic, 630
surgical, 629
Cystogastrostomy, in pancreatic pseudocyst drainage, endoscopic, 627–628, 788–789
laparoscopic, 630
percutaneous, 626–627
surgical, 629
Cytokines, in cholesterol 7α-hydroxylase feedback regulation, 14
in inflammatory bowel disease pathogenesis, 288–290
in inflammatory bowel disease treatment, anti-inflammatory, 332–334
proinflammatory, 325–331
in pancreatitis pathogenesis, 592–593
Cytology, of pancreatic pseudocysts, 622
Cytomegalovirus infections, from immunosuppressive agents, 239
in inflammatory bowel disease, in primary sclerosing cholangitis pathogenesis, 494
Cytosol, bile acid movement in, 36–37

Débridement, in necrotizing pancreatitis, 666
7-Dehydrocholesterol 7-reductase deficiency (Smith-Lemli-Opitz syndrome), 161–162
Diabetes mellitus, exocrine pancreatic disorders in, 559–561
in chronic pancreatitis, 562
in pancreatic cancer, 562–563, 711
pancreatic cancer risk in, 681
prophylactic cholecystectomy in, 124
Diarrhea, after antireflux surgery, 1000
bile acid, in ileal resection or dysfunction, 12
differential diagnosis of, endoscopy in, 410–414
from immunosuppressive agents, 243
in bile acid transport defects, 48–49
in collagenous colitis, 479, 482, 484
in inflammatory bowel disease, in pediatric patients, 446–447
treatment of, 305–306
in lymphocytic colitis, 486–487
in pancreatitis, management of, 691–692
Diet. See also *Nutrition*.
gallstone formation and, 87
in Barrett's esophagus malignant degeneration, 930–932
in chronic pancreatitis. 703–704
in esophageal peptic stricture, 884
in gastroesophageal reflux disease, 832
in pediatric patients, 962
in inflammatory bowel disease pathogenesis, 263
pancreatic cancer risk and, 681
Diffusion, in bile acid transport, 35, 39–41
Difluoromethylornithine, Barrett's esophagus malignant degeneration and, 939
Dilation, of esophageal peptic stricture, 886–887
Disuse (diversion) colitis, 487–488
Diverticula, pancreatic, pancreatitis in, 577–578
DNA aneuploidy, in Barrett's esophagus malignant degeneration, 937
Docosahexaenoic acid, in inflammatory bowel disease, 338, 434, 455
Domperidone, in gastroesophageal reflux disease, 838, 897
Drugs, combined with bile acid transporters, 49
gallstone formation and, 88, 108–109
gastroesophageal reflux disease due to, 832
pancreatitis due to, 575
Dual-probe pH monitoring, in esophagus, 816–817
Duodenal reflux hypothesis, of gallstone pancreatitis, 602
Dyslipidemia, bile salt enterohepatic circulation and, 221–222
therapeutic manipulation of, 223–225
Dysphagia, after antireflux surgery, 999–1000
after fundoplication, 1014
from immunosuppressive agents, 242
in Barrett's esophagus, 921
in gastroesophageal reflux disease, 812, 989
in peptic stricture, 880, 951
Dysphonia, in gastroesophageal reflux disease, 867–869

Ear disorders, in gastroesophageal reflux disease, 867–869
Eicosapentaenoic acid, in inflammatory bowel disease, 338, 434, 455
Elderly persons, gastroesophageal reflux disease in, 813
inflammatory bowel disease in, 275–276
Endocrine tumors, of pancreas, endoscopic ultrasonography in, 753–754

Endoluminal ultrasonography. See *Ultrasonography, of pancreas, endoluminal (intraductal).*
Endoscopic retrograde cholangiopancreatography, in acute pancreatitis, 784–785
in cancer, 716, 795
in chronic pancreatitis, 786
versus endoscopic ultrasonography, 755–758
in gallstone pancreatitis, 784–785
indications for, 604–605
intraoperative, 607
preoperative, 606–607
urgent, 607–610
in iatrogenic biliary injury, 128
in inflammatory bowel disease, 418
in pancreas divisum, 786
in pseudocysts, 623, 788
pancreatitis after, 575
versus laparoscopic exploration, 120–121
Endoscopic ultrasonography. See *Ultrasonography, of pancreas, endoscopic.*
Endoscopy, in esophageal peptic stricture, 881–883
in gastroesophageal reflux disease, 813–814, 881–883, 957–958
in inflammatory bowel disease, 404, 406
in cancer surveillance, 417, 465–468
in differential diagnosis, 410–414
in disease extent evaluation, 414–415
in pediatric patients, 452
in recurrent disease, 416
in treatment response evaluation, 416
preoperative, 416–417
retrograde cholangiopancreatography, 418
therapeutic, 417–418
ultrasonographic, 418
upper, 418
of pancreas, **783–800**
in cancer, 794–796
in pancreatitis, acute, 783–786
chronic, 786–793
for sphincterotomy, 787
gallstone, 784–785
in sphincter of Oddi dysfunction, 785
recurrent, 785–786
with obstructive jaundice, 793
with pancreatic duct stones, 789–790
with pancreatic duct strictures, 790–792
with pseudocysts, 787–789
in pseudocyst drainage, 627–628, 788–789
Enema, barium, in inflammatory bowel disease, 393–394, 396–409
small bowel, with peroral pneumocolon, in inflammatory bowel disease, 392–393
Energy requirements, in inflammatory bowel disease, 426
Enteral nutrition, in inflammatory bowel disease, 305, 430–433
complications of, 430
formulations for, 430–431
in pediatric patients, 455
refractory, 362
Enteroclysis, with peroral pneumocolon, in inflammatory bowel disease, 392–393
Enterocolitis, cytomegalovirus, from immunosuppressive agents, 239
Enteroenteric fistula, in Crohn's disease, treatment of, 362–363
Enterohepatic circulation, of bile salts, 28–31
in lipoprotein metabolism. See *Lipoprotein(s), metabolism of.*
Enteroinsular axis, 557–559
Enteropancreatic axis, 554–559, 688–689
Enterovesical fistula, in inflammatory bowel disease, in pediatric patients, 450
treatment of, 363
Environmental factors, in inflammatory bowel disease, 262–264, 284–285
Enzymatic therapy, for chronic pancreatitis, **687–693**
adverse reactions to, 692
enteropancreatic axis and, 688–689
malabsorption management and, 691–692, 702–703
pain management and, 689–691
preparation composition for, 687–688
for pancreatic cancer, 718
Epidermal growth factor, in inflammatory bowel disease, 434
Epstein-Barr virus infections, from immunosuppressive agents, 240
erb2 gene, in Barrett's esophagus malignant degeneration, 938
ERCP. See *Endoscopic retrograde cholangiopancreatography.*
Erythema nodosum, in inflammatory bowel disease, 268, 449
Escherichia coli, in inflammatory bowel disease pathogenesis, 264
Esophagectomy, in Barrett's esophagus, 993
Esophagitis, differential diagnosis of, 883–884
endoscopy in, 813–814
in gastroesophageal reflux disease, in pediatric patients, 948–949
motility abnormalities in, 909–910
treatment of, in gastroesophageal reflux disease, 848
Esophagogastroduodenoscopy, preoperative, in gastroesophageal reflux disease, 993

Esophagography, in gastroesophageal reflux disease, 817–818
preoperative, 993–994
in peptic stricture, 880–881
Esophagoscopy, in gastroesophageal reflux disease, 813–814
Esophagus, acid-sensitive. See *Gastroesophageal reflux disease, endoscopy-negative.*
adenocarcinoma of. See *Barrett's esophagus, adenocarcinoma development from.*
Barrett's. See *Barrett's esophagus.*
contraction amplitude of, in gastroesophageal reflux disease, 907–908
dilation of, in peptic stricture, 886–887
histopathology of, in gastroesophageal reflux disease, 957–958
in peptic stricture, 878
hypersensitive. See *Gastroesophageal reflux disease, endoscopy-negative.*
lengthening of, 1001, 1009
manometry of, in gastroesophageal reflux disease, 818, 994
motility disorders of, in peptic stricture, 876
obstruction of, dysphagia in, 812
peptic strictures of, **875–891**
clinical features of, 880
diagnosis of, 880–883
differential diagnosis of, 883–884
histopathology of, 878
in pediatric patients, 951
pathophysiology of, 876–878
predisposition to, 878–879
prevalence of, 875–876
treatment of, medical, 884–887
surgical, 887–888, 1008–1009
peristalsis of, in gastroesophageal reflux disease, 905–907
pH monitoring in. See *pH monitoring, in gastroesophageal reflux disease.*
reflexes of, gastroesophageal reflux disease and, 862
reflux into. See *Gastroesophageal reflux disease.*
resection of, in peptic stricture, 888
rings in, peptic stricture in, 879
sensitive, 816
shortened, after antireflux surgery, 1000–1001
sphincter dysfunction in, *Helicobacter pylori* and, 972–973
in gastroesophageal reflux disease, 862, 952, 988
in peptic stricture, 876
Estrogens, cholestasis from, ursodeoxycholic acid effects on, 200–201
gallstone formation and, 86
Ethnic factors, in inflammatory bowel disease, 259–260
Ethyl propionate, for gallstone dissolution, 140
Evening primrose oil, in inflammatory bowel disease, 435
Exclusion (diversion) colitis, 487–488
Executive pancreatitis, 573–574
Extracorporeal shock-wave lithotripsy, for gallstone dissolution, 138–139

Facilitative transport, of bile acids, 34–35
Familial intrahepatic cholestatic syndromes, 42–48, 145–146
Alagille syndrome, 43, 46–47
benign recurrent intrahepatic cholestasis, 43, 45–46
Blyler's disease and Blyler's syndrome, 43–45, 69–70, 166–168, 188
Native American cholestasis, 43, 47–48
nonsyndromic paucity of bile ducts, 43, 47
Norwegian cholestasis, 43, 48
progressive, 43–45, 166–168
subtypes of, 69–72
Familial pancreatitis. See *Hereditary pancreatitis.*
Famotidine, in gastroesophageal reflux disease, 834–835, 840, 899
Fasting, gallstone formation and, 106
Fatty acids, short-chain, in diversion colitis, 488
in inflammatory bowel disease, 305, 338–339, 433–434
Fatty liver, in inflammatory bowel disease, 506
Feathery degeneration, in cholestasis, 196–197
Fibrosing cholestatic hepatitis, in hepatitis B, 240
FIC1 gene, in Blyler's syndromes, 44–45, 70
Fine-needle aspiration, of pancreas, in cancer, 715, 751–753
in pancreatitis staging, 663–664
Fish oils, in inflammatory bowel disease, 338, 434
in pediatric patients, 455
steroid-refractory, 357
Fistulas, in inflammatory bowel disease, in pediatric patients, 448–450
radiography of, 408–409
treatment of, 362–363
in pancreatic pseudocysts, 632
Flippase activity, in biliary lipid secretion, 63
Fluid collections, versus pancreatic pseudocysts, 616–617
Fluoroscopy, in gastroesophageal reflux disease, 956–957

5-Fluorouracil, in pancreatic cancer, 718–719
Folic acid, in inflammatory bowel disease, in cancer prevention, 464
Free radical inhibitors, in inflammatory bowel disease, 338
Fundoplication, in gastroesophageal reflux disease, **1007–1019**
  assessment of, 1012
  atypical, 1009–1010
  complicated, 1008–1009
  complications of, 1007–1008, 1014–1017
  evaluation before, 1010–1011
  failure of, 1007–1008
  in hiatal hernia, 1010
  in pediatric patients, 964–965
  ineffective, 1012, 1014
  laparoscopic, 995–996
  new symptoms after, 1014–1017
  Nissen. See *Nissen fundoplication.*
  patient selection for, 1008–1011
  postoperative management in, 1012, 1014
  refractory, 1009
  repeat, 1016–1017
  results of, 995
  surgeon selection for, 1011–1012
  technique selection for, 1011
  uncomplicated, 1010
  with Barrett's esophagus, 1008–1009
  with peptic stricture, 1008–1009
Fungal infections, from immunosuppressive agents, 241

Gallbladder, cancer of, as gallstone complication, 135
  laparoscopic surgery for, 125
  gallstone formation and. See Gallstones.
  laparoscopic surgery on. See *Laparoscopic biliary surgery.*
  polyps of, laparoscopic surgery for, 124–125
  porcelain, cancer risk in, 135
  prophylactic cholecystectomy in, 118
Gallstone pancreatitis, **601–613**
  acute, 574–575
    conservative management of, 606
    diagnosis of, 602–604
    endoscopic retrograde cholangiopancreatography in, indications for, 604–605
      intraoperative, 607
      preoperative, 606–607
      urgent, 607–610
    outcome prediction in, 605–606
    severity of, 605–606
    surgical treatment of, 606–607
  endoscopic ultrasonography in, 762
  endoscopy in, 784–785
  laboratory tests in, 603–604
  pathogenesis of, 601–602
  recurrent, 574–575
Gallstones, cholesterol homeostasis and, 1–3
  complications of, 134–135
  composition of, 75–76
  epidemiology of, 133
  formation of, **75–97**, **99–115**
    age factors in, 86
    biliary lipid aggregates and, 76–78
    biliary lipid secretion and, 78–80
    cholesterol. See *Cholesterol gallstones.*
    cholesterol hypersecretion and, 82–83
    dietary factors in, 87
    drug-induced, 88, 108–109
    estrogens and, 86
    gallbladder factors in, 83–84, 102–104
    genetic factors in, 87–88, 107–108
    hyperlipidemia and, 87
    in inflammatory bowel disease, 273, 503, 506
    in pregnancy, 86, 123–124
    in spinal cord injury, 88
    infections and, 85, 89–90, 104–105
    intestinal bile salt metabolism and, 84
    intestinal hypomotility and, 87
    metabolic factors in, 85–88
    mixed composition, 85
    obesity and, 86
    pigment, 88–91, 105–107
    rapid weight loss and, 86
    vicious cycle of, 80, 82
  laparoscopic surgery for, **117–132**
  mortality with, 136
  nonsurgical management of, **133–144**
    asymptomatic, 135
    extracorporeal shock-wave lithotripsy in, 138–139
    oral cholelitholytic therapy in, 138
    symptomatic, 135–136
    topical dissolution therapy in, 139–140
  pancreatitis in, 134–135. See *Gallstone pancreatitis.*
    laparoscopic surgery for, 122–123
  risk factors for, 133–134
  types of, 75–76
Gamma-linoleic acid, in inflammatory bowel disease, 435
Gas-bloat syndrome, after antireflux surgery, 1000, 1014–1015
Gastric acid, reflux of. See *Gastroesophageal reflux disease.*
Gastric emptying, delayed, in gastroesophageal reflux disease, 953–954, 977, 988–989
  in pancreatic cancer, 713
Gastric inhibitory peptide, in pancreatic secretion regulation, 556–557

Gastrin, excess of, in *Helicobacter pylori* infections, 974–975
Gastrinoma, endoscopic ultrasonography in, 753–754
Gastritis, in *Helicobacter pylori* infections, 975–978
Gastroduodenal Crohn's disease, treatment of, 358–359
Gastroesophageal reflux disease, alkaline, peptic stricture in, 877
asymptomatic, 809
atypical, 989
surgical treatment of, 1009–1010
Barrett's esophagus and. See *Barrett's esophagus*.
classification of, 893–894
clinical features of, 809–813, 989
in pediatric patients, 948–949
spectrum of, 810–811
with peptic stricture, 880
complicated, surgical treatment of, 1008–1009
complications of, 824
in pediatric patients, 950–952
surgery for, 992
course of, in pediatric patients, 950–952
definition of, 809, 908
diagnosis of, **809–830**
endoscopy in, 813–814
in extraesophageal manifestations, 864
in pediatric patients, 955–961
incorrect, 851–852
manometry in, 818
optimizing, 820–824
pH monitoring in, 814–817
provocative testing in, 818
radiologic testing in, 817–818
refractory, 853–854
therapeutic trial in, 818–820
with peptic stricture, 880–883
differential diagnosis of, in pediatric patients, 956
with peptic stricture, 883–884
endoscopy-negative, **893–904**
clinical features of, 896–897
prevalence of, 895–896
psychologic factors in, 898–899
significance of, 897–898
treatment of, 900–901
epidemiology of, 809
Helicobacter pylori and, 978–980
in pediatric patients, 947
with peptic stricture, 875–876
esophageal strictures in, **875–891**
extraesophageal manifestations of, 820, 822–823, **861–873**
asthma, 865–866, 949–950, 1009–1010
chest pain, 812, 863–864, 989
cough, 864–865, 1009–1010
idiopathic pulmonary fibrosis, 867
in pediatric patients, 949–950
otolaryngologic, 813, 822–823, 867–869, 949
pathophysiology of, 862–863
treatment of, 869
gastric compliance in, 953
Helicobacter pylori and, **971–985**
histopathology of, with peptic stricture, 878
in elderly persons, 813
in pediatric patients, **947–969**
motility abnormalities in, **905–915**
antireflux surgery modifications for, 913–914
change in contraction amplitude, 907–908
classification of, 908
decreased peristalsis percentage, 905–907
esophageal body, 908–911, 988
reversibility of, 911–913
natural history of, 989–990
nocturnal gastric acid breakthrough in, 851, 855, 864, 869
nonacid, versus acid, 854
otolaryngologic conditions in, 813, 822–823, 867–869, 949
pathophysiology of, 987–989
extraesophageal manifestations, 862–863
Helicobacter pylori and, 972–977
in pediatric patients, 952–955
with peptic stricture, 876–878
physiologic, 948–950
predisposition to, with peptic stricture, 878–879
prevalence of, *Helicobacter pylori* and, 978–980
in pediatric patients, 947
provocative meal volume and, 953
refluxate components in, 952
refractory, diagnosis of, 853–854
importance of, 853
treatment of, **847–860**, 1009
spectrum of, in pediatric patients, 948
spontaneous resolution of, 950
treatment of, antireflux surgery in, **987–1005**
complications of, **1007–1019**
conservative, 961–962
efficacy of, 848–849
extraesophageal, 869
failure of, 823–824, 850–853, 1016–1017
goals of, 847–848
Helicobacter pylori and, 977–978, 980–981
in diagnostic evaluation, 818–820
in pediatric patients, 961–965
medical, **847–860**, 990–991
acid suppression in, 834–837

Gastroesophageal reflux disease *(Continued)*
combination therapy in, 839–840
in pediatric patients, 962–964
maintenance therapy in, 840
nonpharmacologic, 832
overview of, **831–845**
patient-directed, 832–834
promotility agents in, 837–839
with peptic stricture, 884–887
optimization of, 854–856
proton-pump inhibitors in. See *Proton-pump inhibitors*; specific drugs.
refractory, **847–860**
surgical. See also *Fundoplication*; *Nissen fundoplication.*
complications of, 998–1001
evaluation before, 993–994
in pediatric patients, 964–965
in refractory disease, 856
indications for, 991–993
motility and, 912–914
postoperative course of, 998
predictors of success or failure, 999
procedures for, 994–998
results of, 999
with peptic stricture, 887–888
with cough, 865, 1009–1010
Gastrojejunostomy, in pancreatic cancer, 717
Gastroplasty, in peptic stricture, 887–888
in shortened esophagus, 1001, 1009
Gastrostomy feeding, in gastroesophageal reflux disease, in pediatric patients, 965
Gender, Barrett's esophagus and, 922–923
inflammatory bowel disease and, 257–259
Gene therapy, for hereditary pancreatitis, 536–537
Genetic factors, in Barrett's esophagus malignant degeneration, 934–939
in gallstone formation, 87–88, 107–108
in *Helicobacter pylori* infections, 976–977
in inflammatory bowel disease, 260–262, 284–285
in pancreatic cancer, 678, 682
in pancreatic exocrine-endocrine interrelationships, 563–565
in primary sclerosing cholangitis, 495
GERD. See *Gastroesophageal reflux disease.*
Giant cell hepatitis, in 3β-hydroxysteroid dehydrogenase deficiency, 155–160
Globus, in gastroesophageal reflux disease, 867–869
Glucagon, excess of, in hyperglycemia, 562
exocrine pancreas interactions with, 554
in cholesterol 7α-hydroxylase feedback regulation, 14
secretion of, 553
Glucose-dependent insulinotropic polypeptide (gastric inhibitory peptide), in pancreatic secretion regulation, 556–557
β-Glucuronidase, gallstone formation and, 106
Glutamine, in inflammatory bowel disease, 434
Glycoproteins, in bile formation, 61–63
Graft-versus-host disease, in transplantation, 241–242
Growth failure, of inflammatory bowel disease, 451

Harris-Benedict equation, for caloric requirements, in inflammatory bowel disease, 426
in pancreatitis, 699–700
Hartmann procedure, in ulcerative colitis, 374–375
Heartburn, description of, 811
in Barrett's esophagus, 921
in gastroesophageal reflux disease, 811, 989
endoscopy-negative, 895–896
in peptic stricture, 880
prevalence of, 809
Helicobacter pylori infections, gastroesophageal reflux disease and, 850, **971–985**
acid-suppressive therapy effects on, 977–978
epidemiology of, 971–972
eradication studies of, 980–981
pathophysiology of, 972–977
prevalence of, 978–980
Hematologic malignancies, in inflammatory bowel disease, 471–472
Hemorrhage, in inflammatory bowel disease, 266, 373, 497–498
in pancreatic pseudocysts, 633–634
Hemosuccus pancreaticus, in pancreatic pseudocyst, 634
Heparin, in inflammatory bowel disease, 340
Hepatitis, chronic, in inflammatory bowel disease, 450, 506–507
giant cell, in 3β-hydroxysteroid dehydrogenase deficiency, 155–160
herpetic, from immunosuppressive agents, 240
viral, from immunosuppressive agents, 240
Hepatitis B, from immunosuppressive agents, 240–241
Hepatitis C, from immunosuppressive agents, 240–241

Hepatobiliary disease, in inflammatory bowel disease, 268–269, 273, **491–513**. See also *Primary sclerosing cholangitis.*
cholelithiasis, 273, 503, 506
chronic hepatitis, 450, 506–507
fatty liver, 506
in pediatric patients, 450
pericholangitis, 506
types of, 491
Hepatocytes, bile acid toxicity to, ursodeoxycholic acid effects on, 201
Hepatoprotective effects, of bile acids, **195–209**
antioxidant, 203
immunomodulatory, 203–204
in cholestasis, 195–197
animal studies of, 200
bile flow increase, 198–200
estrogen-induced, 200–201
secretory improvement, 198–200
toxic bile acid displacement, 197–198
in hepatocyte culture, 201
in primary biliary cirrhosis, 181–183, 203
on membranes, 201–203
on mitochondria, 201–203
Hereditary pancreatitis, **525–541**
acute, 583–584
cancer risk in, 527, 676–677
chronic, 536
clinical spectrum of, 526–528
complications of, 525, 527
gene therapy for, 536–537
penetrance rate in, 527
trypsin activation prevention and, 533
trypsinogen mutations in, 528–536
acute pancreatitis initiation in, 533–536
mechanistic hypothesis of, 530–533
Hernia, hiatal, gastroesophageal reflux disease in, 877–878, 911, 1010
Herpes simplex virus infections, from immunosuppressive agents, 239–240
Hiatal hernia, gastroesophageal reflux disease in, 877–878, 911, 1010
Hill procedure, in gastroesophageal reflux disease, 996–997
Histamine$_2$-receptor antagonists, in Barrett's esophagus, 920
in gastroesophageal reflux disease, 834, 848–849, 990
endoscopy-negative, 901
in pediatric patients, 964
motility and, 911–912
Hoarseness, in gastroesophageal reflux disease, 867–869
Hodgkin's lymphoma, in inflammatory bowel disease, 274, 471–472
Human immunodeficiency virus infection, primary sclerosing cholangitis in, 494
Human leukocyte antigens, in inflammatory bowel disease, 284
Hydrocortisone, in inflammatory bowel disease, 301
Hydronephrosis, in inflammatory bowel disease, 450
Hydroxychloroquine, in inflammatory bowel disease, 340
27-Hydroxycholesterol, synthesis of, 8
25-Hydroxylase deficiency, cholestasis in, 161
7α-Hydroxylation, of cholesterol, defects of, 162–164
3-Hydroxy–3-methylglutaryl reductase inhibitors, for lipid-lowering, 223
3β-Hydroxysteroid dehydrogenase deficiency, 18, 71, 155–160
Hyperbaric oxygen therapy, in inflammatory bowel disease, 340
Hypercholesterolemia, bile salt enterohepatic circulation and, 222
therapeutic manipulation of, 223–225
cholesterol homeostasis and, 1–3
Hyperchylomicronemia, bile salt enterohepatic circulation and, 222
therapeutic manipulation of, 223–225
Hypergastrinemia, in *Helicobacter pylori* infections, 974–975
Hyperglucagonemia, in hyperglycemia, 562
Hyperglycemia, hyperglucagonemia in, 562
Hyperlipidemia, bile salt enterohepatic circulation and, 221–222
gallstone formation and, 87
pancreatitis in, 576
Hypermetabolism, in pancreatitis, 695–696
Hypersensitive esophagus. See *Gastroesophageal reflux disease, endoscopy-negative.*
Hypertriglyceridemia, bile salt enterohepatic circulation and, 222
therapeutic manipulation of, 223–225
gallstone formation and, 87

Idiopathic pulmonary fibrosis, gastroesophageal reflux disease and, 867
Ileal lipid-binding protein, in bile acid transport, 41–42
Ileal sodium-dependent bile acid transporter, 41
Ileitis, in inflammatory bowel disease, backwash, 396
treatment of, 359
Ileoanal anastomosis, in Crohn's disease, 387
in ulcerative colitis, 374–383

Ileoanal anastomosis *(Continued)*
advantages of, 376–377
complications of, 380–382
in cancer prevention, 465
patient selection for, 377
procedure for, 377, 379–380
results of, 377–379, 382–383
Ileocolic fistula, in Crohn's disease, radiography of, 408
Ileocolitis, in Crohn's disease, 359
Ileoscopy, in inflammatory bowel disease, 414
Ileostomy, diversion colitis in, 487–488
in Crohn's disease, 386–388
in ulcerative colitis, Brooke, 374–375
continent, 375–376
in cancer prevention, 465
with proctocolectomy, 374
Ileovesical fistula, in Crohn's disease, radiography of, 408
Ileum, bile acid transport in, 30–31, 41
radiography of, in inflammatory bowel disease, 392–393
Imipenem, prophylactic, in pancreatitis, 648–649, 651–652, 655–656
Immune system, dysfunction of, in primary sclerosing cholangitis pathogenesis, 495–496
Immunoadhesins, in inflammatory bowel disease, 331
Immunocholangitis, 174
Immunoglobulin(s), intravenous, in inflammatory bowel disease, 341
Immunomodulators, in inflammatory bowel disease, 301–304
refractory, 361
Immunomodulatory effects, of ursodeoxycholic acid, 203–204
Immunosuppressive agents, for primary biliary cirrhosis, 174
gastrointestinal complications of, **233–245**
abdominal pain, 242
abnormal liver function, 243
diarrhea, 243
drug characteristics and, 234–238
dysphagia, 242
fungal infections, 241
graft-versus-host diseases, 241–242
nausea and vomiting, 242
viral infections, 239–241
in inflammatory bowel disease, 306–307, 334
in pediatric patients, 455
Immunotherapy, for inflammatory bowel disease, 290–291
Infections, from immunosuppressive agents, 238–241
gallstone formation and, 104–105
brown pigment, 89–90
cholesterol, 85
in inflammatory bowel disease, pathogenetic effects of, 264
primary sclerosing cholangitis and, 494
in pancreatitis, **641–659**
antibiotic prophylaxis of, in severe acute cases, 648–654
selective gut decontamination in, 652–654
tissue penetrability and, 643, 645–648
bacteriology of, 664–665
diagnosis of, 642, 664–665
epidemiology of, 642
microorganisms causing, 644
pathogenesis of, 642–643
prognosis for, 667
risk factors for, 663–664
surgical treatment of, 665–667
of pancreatic pseudocysts, 632
Inflammatory bowel disease, atypical, **479–490**
caloric requirements in, 426
cancer in. See *Cancer, in inflammatory bowel disease.*
clinical features of, in pediatric patients, 446–447
complications of, 266–269, 447–449
diagnosis of, in pediatric patients, 451–453
differential diagnosis of, endoscopy in, 410–414
in pediatric patients, 452–453
endoscopy in. See *Endoscopy, in inflammatory bowel disease.*
energy requirements in, 426
environmental factors in, 262–264, 284–285
epidemiology of, 255–260
age trends in, 256–257
ethnic trends in, 259–260
gender in, 257–259
geographic trends in, 255–256
in pediatric patients, 445–446
racial trends in, 259
socioeconomic factors in, 260
time trends in, 256
urban-rural differences in, 260
extraintestinal manifestations of, 267–269, 271, 273–274
in pediatric patients, 449–450
genetic factors in, 260–262, 284–285
growth failure in, 451
hepatobiliary disease in. See *Hepatobiliary disease, in inflammatory bowel disease; Primary sclerosing cholangitis.*
heterogeneity of, 285
imaging of, **391–421**
endoscopy in, 404, 406, 410–418

radiography in, 392–409
in elderly persons, 275–276
in pediatric patients, 275, **445–458**
infections in, in primary sclerosing cholangitis pathogenesis, 494
natural history of, 265–275
nutrition in. See *Nutrition, in inflammatory bowel disease.*
pathogenesis of, **283–296**
animal models of, 288–290
disease heterogeneity and, 285
environmental factors in, 262–264, 284–285
genetic factors in, 260–262, 284–285
theories on, 286–288
protein requirements in, 426
quality of life in, 270, 274–275
radiography in, contrast luminal, 392–395
features of, 394, 396–405
plain abdominal film in, 392
risk factors for, 260–265
survival in, 269–270, 274
treatment of, adhesion molecule inhibitors in, 336–337
aminosalicylates in. See *5-Aminosalicylates.*
anesthetics in, 336
antibiotics in, 304–305, 324–325, 356, 360, 455
antigen-directed, 323–325
arachidonic acid metabolites in, 337–338
biologic approaches to, 306–307
bismuth subsalicylate in, 339
chloroquine in, 340
clinical presentation and, **353–370**
corticosteroids in. See *Corticosteroids.*
cytokines in, anti-inflammatory, 332–334
proinflammatory, 325–331
free radical inhibitors in, 338
heparin in, 340
hydroxychloroquine in, 340
hyperbaric oxygen therapy in, 340
immunoglobulins in, 341
immunomodulators in, 301–304, 361
immunosuppressive agents in, 306–307, 334, 455
immunotherapy in, 290–291
in pediatric patients, 453–456
interferon-α in, 340
investigational therapies in, 306–307
ketotifen in, 340
leukapheresis in, 341
medical, **297–321**
in pediatric patients, 454–456
nutritional. See *Nutrition, in inflammatory bowel disease.*
nutritional deficiencies in, 425–426
neuroimmunomodulators in, 334–336
nicotine in, 307, 339, 357
novel, **323–351**
in pediatric patients, 455–456
nutrition and. See *Nutrition, in inflammatory bowel disease.*
probiotics in, 325
recruitment blockers in, 336–337
reparative enhancers in, 338
short-chain fatty acids in, 305, 338–339, 433–434, 488
supportive therapy in, 305–306
surgical, **371–390**
in cancer prevention, 464–465
in pediatric patients, 454–455
nutritional therapy before, 428
versus diversion colitis, 488
Infliximab, in inflammatory bowel disease, 306, 327–330
Insulin, exocrine pancreas interactions with, 554
in cholesterol 7α-hydroxylase feedback regulation, 14
secretion of, 553–554
Insulinoma, computed tomography of, 726
endoscopic ultrasonography in, 753–754
Intercellular adhesion molecule 1 antisense oligonucleotide, in inflammatory bowel disease, 337
Interferon-α, in inflammatory bowel disease, 340
Interleukin(s), in pancreatitis pathogenesis, 592–593
inhibitors of, in pancreatitis, 593–598
Interleukin–6, in inflammatory bowel disease, 333–334
Interleukin–10, in inflammatory bowel disease, 306, 332–333
Interleukin–11, in inflammatory bowel disease, 306, 334
Interlobular hepatitis (pericholangitis), in inflammatory bowel disease, 506
Intestinal factor, in cholesterol 7α-hydroxylase feedback regulation, 14
Intestine, bile acid transport in, 30–31, 39–42
defects of, 48–49
bile salt metabolism in, gallstone formation and, 84
hypomotility of, gallstone formation and, 87
selective decontamination of, in pancreatitis, 652–654
Intraductal ultrasonography. See *Ultrasonography, of pancreas, endoluminal (intraductal).*
Intubation, nasogastric, esophageal peptic stricture in, 879
Islet amyloid polypeptide, in pancreatic cancer, 711

Islet cells, anatomy of, 552–553
function of, 552–553
tumor-associated, 563
Islet-acinar axis, 554–559

Jaundice, in pancreatic pseudocysts, 634
in primary sclerosing cholangitis, 496
obstructive, pancreatic endoscopy in, 793

Ketotifen, in inflammatory bowel disease, 340
Ki–67 antigen, as marker, for Barrett's esophagus malignant degeneration, 938
Kidney stones, in inflammatory bowel disease, 450
Kock continent ileostomy, in ulcerative colitis, 375–376

Lactate dehydrogenase, in pancreatitis staging, 663
Lansoprazole, in Barrett's esophagus, 1008
in esophageal peptic stricture, 885
in gastroesophageal reflux disease, 835–837, 840, 849
high-dose, 849
in pediatric patients, 964
pharmacology of, 849–850
refractory, 855
with extraesophageal manifestations, 869
Laparoscopic biliary surgery, **117–132**
bypass, 129
complications of, 125–129
contraindications to, 119
conversion to open procedure, 118, 128
in cancer, 125
in children, 123
in cholangitis, 123
in cholecystitis, 119–120
in choledocholithiasis, 120–122
in gallstone disease, 136–137
asymptomatic, 118
complicated, 119–123
pancreatic, 122–123
symptomatic, 119
in polyp removal, 124–125
in pregnancy, 123–124
prophylactic, in diabetes mellitus, 124
technical aspects of, 117–118
Laparoscopic surgery, in gastroesophageal reflux disease, 995–999
Laparoscopy, in pancreatic cancer staging, 715–716, 795
Laryngeal cancer, in gastroesophageal reflux disease, 867–869
Laser therapy, for Barrett's esophagus, 920
Lecithin cholesterol acyltransferase, in lipoprotein metabolism, 219–220
Leukapheresis, in inflammatory bowel disease, 341
Lexipafant, in pancreatitis, **591–599**
basis for, 591–593
clinical studies of, 593–598
Lidocaine, in inflammatory bowel disease, 336
Lifestyle changes, in esophageal peptic stricture, 884
in gastroesophageal reflux disease, 832, 961–962, 990
Lincomycin, prophylactic, in pancreatitis, 656–657
Lipase pancreatic enzyme preparation, in chronic pancreatitis, 691–692, 702–703
Lipid(s), biliary. See *Biliary lipids; Cholesterol.*
Lipid-lowering drugs, bile salt enterohepatic circulation and, 223–225
gallstone formation and, 88
Lipoprotein(s), metabolism of, **211–229**
apoproteins in, 212–213
bile salts in, in hyperlipidemia, 221–222
therapeutic use of, 223–225
chylomicrons and, 214–215
high-density, 212, 219–221
low-density, 212–213, 217–219
in hyperlipidemia, 222
overview of, 214
versus class, 211–212
very-low-density, 216–217
lith1 gene and product, gallstone formation and, 107–108
Lithiasis, gallbladder. See *Gallstones.*
renal, in inflammatory bowel disease, 450
Lithotripsy, extracorporeal shock-wave, for gallstone dissolution, 138–139
in pancreatic stone treatment of, 790
Liver, disease of, in inflammatory bowel disease. See *Hepatobiliary disease, in inflammatory bowel disease; Primary sclerosing cholangitis.*
fatty, in inflammatory bowel disease, 506
protection of. See *Hepatoprotective effects.*
transplantation of, in primary sclerosing cholangitis, 505
Liver function tests, in immunosuppressive therapy, 243
Loperamide, in inflammatory bowel disease, for remission maintenance, 360
Luminal cholecystokinin-releasing factor, 556

Lymphocytic colitis, 481, 486–487
Lymphoma, from immunosuppressive agents, 240
in inflammatory bowel disease, 274, 471–472

α_2-Macroglobulin deficiency, in pancreatitis, 591–592
Magnesium hydroxide, in gastroesophageal reflux disease, 833
Magnesium trisilicate, 833
Magnetic resonance imaging, of pancreas, 732, 739–742
contrast agents for, 741
in cancer, 715, 740–742
normal, 739
Malabsorption, in inflammatory bowel disease, 425
in pancreatic insufficiency, in cystic fibrosis, 543–544
in pancreatitis, management of, 691–692
nutritional supplementation in, 695–707
Malnutrition, in inflammatory bowel disease, 423–426
Maloney and Hurst dilators, in peptic stricture, 886–887
Manometry, biliary, in sphincter of Oddi dysfunction, 582–583
esophageal, in gastroesophageal reflux disease, 818, 994
MCC gene, mutations of, in Barrett's esophagus malignant degeneration, 936
Mdr2 gene and product, in bile formation, 61–63
MDR3 gene and product, in bile formation, 62–63
in progressive familial intrahepatic cholestatic syndromes, 45, 68, 70, 168
Measles virus, in inflammatory bowel disease pathogenesis, 264
Megacolon, toxic, in inflammatory bowel disease, 373–374, 448
6-Mercaptopurine, in inflammatory bowel disease, 301–303
cancer risk of, 472
in pediatric patients, 454
refractory, 361
steroid-refractory, 356–357
with fistulas, 363
Mesalamine. See *5-Aminosalicylates*.
Metabolism, in pancreatitis, 695–696
Metaplasia, Barrett's. See *Barrett's esophagus*.
Metastasis, from esophageal adenocarcinoma, 919
Methotrexate, in inflammatory bowel disease, 303
refractory, 361–362
steroid-refractory, 357
Methyl tert-butyl ether, for gallstone dissolution, 139–140
Methylprednisolone, in inflammatory bowel disease, 301
Metoclopramide, in gastroesophageal reflux disease, 837, 839, 991
in pediatric patients, 963
Metronidazole, in inflammatory bowel disease, 304–305, 325
ileal, 359
in pediatric patients, 455
perianal, 363
with fistulas, 363
prophylactic, in pancreatitis, 649, 651–652, 655–657
Mezlocillin, prophylactic, in pancreatitis, 656–657
Microlithiasis, biliary, pancreatitis in, 580–582, 604
Microsomal epoxide hydrolase, as bile acid transporter, 34
Mitochondrial membranes, ursodeoxycholic acid effects on, 202–203
Monoclonal antibodies, immunosuppressive, gastrointestinal complications of, 235–238
in inflammatory bowel disease, 327–330
Motility disorders, esophageal, in gastroesophageal reflux disease, **905–915**, 988
in peptic stricture, 876
intestinal, gallstone formation in, 87
Mouth, gastroesophageal reflux disease manifestations in, 813
ulceration of, in inflammatory bowel disease, 449
Mucin, gallstone formation and, 84, 100–103
Mucinous duct ectasia, pancreatitis in, 576
Mucosa addressin cell adhesion molecule 1, antibodies to, in inflammatory bowel disease, 337
Muricholates, hepatoprotective effects of, 204
Mutations, of cystic fibrosis transmembrane conductance regulator gene, frequency of, 545–546
pancreatitis in, 546–548
of trypsinogen genes, in hereditary pancreatitis, 528–536
of tumor-suppressor genes, in Barrett's esophagus malignant degeneration, 934–937
Mycobacterium paratuberculosis, in inflammatory bowel disease pathogenesis, 264, 325

Mycophenolate mofetil, gastrointestinal complications of, 235–237
in inflammatory bowel disease, 306, 334

Nasal disorders, in gastroesophageal reflux disease, 867–869
Nasogastric intubation, esophageal peptic stricture in, 879
Native American cholestasis, 43, 47–48
Nausea and vomiting, after antireflux surgery, 1000, 1015–1016
from immunosuppressive agents, 242
Necrotizing pancreatitis, **661–671**
diagnosis of, 662–663
fulminating, 665
infections in, antibiotic prophylaxis in, 650–652
bacteriology of, 664–665
diagnosis of, 664–665
risk factors for, 642, 663–664
surgical treatment of, 665–667
prognosis for, 667
pseudocyst after, 617
surgical treatment of, 665–666
rationale for, 661–662
Neomycin, in selective gut decontamination, in pancreatitis, 652
Neonatal intrahepatic cholestasis, differential diagnosis of, 153
in 3-oxosteroid 5β-reductase deficiency, 151–155
Nephrolithiasis, in inflammatory bowel disease, 450
Neuroimmunomodulators, in inflammatory bowel disease, 334–336
Neutropenic colitis, from immunosuppressive agents, 242
Nicotine, in inflammatory bowel disease, 307, 339
steroid-refractory, 357
Nissen fundoplication, in Barrett's esophagus, 921
in gastroesophageal reflux disease, 856–857
complications of, 999–1000
indications for, 1011
motility and, 912–914
results of, 996
technique for, 994–995, 1011
in peptic stricture, 887–888
Nizatidine, in gastroesophageal reflux disease, 834–835
Nodules, vocal cord, in gastroesophageal reflux disease, 867–869
Nonsteroidal anti-inflammatory drugs, esophageal peptic stricture from, 879
Nonsyndromic paucity of intrahepatic bile ducts, 43, 47
Norfloxacin, in selective gut decontamination, in pancreatitis, 654
Norwegian cholestasis, 43, 48
Nose, disorders of, in gastroesophageal reflux disease, 867–869
Ntcp protein, as bile acid transporter, 34
Nuclear factor-kappa B, in inflammatory bowel disease, 331
Nucleation, in gallstone formation, 84–85, 100–102
Nutrition, in Barrett's esophagus malignant degeneration, 930–932
in collagenous colitis, 485
in gastroesophageal reflux disease, in pediatric patients, 962
in inflammatory bowel disease, 305, **423–443**
assessment of, 426–427
deficiencies, 423–426, 451
enteral, 305, 362, 430–433, 455
future directions in, 433–436
in pediatric patients, 451, 455
parenteral, 305, 362, 427–430
in pediatric patients, 455
refractory, 362
Nutrition supplementation, in pancreatitis, **695–707**
acute, 695–701
caloric requirements for, 699–700
chronic, 701–704
effects of, 697–698
enzyme replacement with, 702–703
metabolic changes and, 695–696
pancreatic secretion and, 696–697
recommendations for, 698–704
refeeding initiation in, 701
routes for, 699
vitamins in, 700–701

OATP1 protein, as bile acid transporter, 34–35
Obesity, gallstone formation and, 86
in Barrett's esophagus malignant degeneration, 930–932
Octreotide, gallstone formation and, 108–109
in inflammatory bowel disease, 335
Ofloxacin, prophylactic, in pancreatitis, 649, 651, 655–656
OKT3 monoclonal antibodies, gastrointestinal complications of, 235–237
Omeprazole, in Barrett's esophagus, 920
in esophageal peptic stricture, 884–885
in gastroesophageal reflux disease, 835–837, 839–840, 849, 990–991
diagnostic, 818–820, 853, 864
endoscopy-negative, 900–901

failure of, 824
high-dose, 849
in pediatric patients, 964
motility and, 911
pharmacology of, 849–850
refractory, 855
resistance to, 851, 854–855
with extraesophageal manifestations, 869
with otolaryngologic conditions, 868–869
Oncogenes, in Barrett's esophagus malignant degeneration, 938–939
Oral contraceptives, inflammatory bowel disease risk in, 263
Ornithine decarboxylase, Barrett's esophagus malignant degeneration and, 938–939
Osteomalacia, in inflammatory bowel disease, 273
Otolaryngologic conditions, in gastroesophageal reflux disease, 813, 822–823, 867–869
in pediatric patients, 949
3-Oxosteroid–5β-reductase deficiency, 18, 151–155
Oxygen therapy, hyperbaric, in inflammatory bowel disease, 340
Oxysterol 7α-hydroxylase, in bile acid synthesis, 17

P glycoprotein, sister of, in bile acid transport, 39, 62, 80
p53 tumor-suppressor gene, mutations of, in Barrett's esophagus malignant degeneration, 934–936
Pain, abdominal, from immunosuppressive agents, 242
after cholecystectomy, 137
biliary, in gallstone disease, 135–136
chest, in gastroesophageal reflux disease, 863–864, 989
in gastroesophageal reflux disease, 812
in pancreatic cancer, 710–711, 713, 718
in pancreatic pseudocyst, 621
in pancreatitis, 689–691
Pancolitis, in ulcerative colitis, treatment of, 354–355
Pancreas, anatomic abnormalities of, endoscopic ultrasonography of, 764
pancreatitis in, 577
anatomy of, 551–555
antibiotic penetration of, 643, 645–648
cancer of. See *Cancer, pancreatic.*
cysts of, differential diagnosis of, 617
endoluminal ultrasonography of, 776–777
endoscopic ultrasonography in, 754–755
pancreatitis in, 578
diverticula of, pancreatitis in, 577–578
endoscopy of. See *Endoscopic retrograde cholangiopancreatography; Endoscopy, of pancreas.*
exocrine-endocrine interrelationship of, **551–569**
anatomic, 551–555
functional, 555–559
in cancer, 562–563
in diabetes mellitus, 559–561
in genetic disorders, 563–565
in pancreatitis, 561–563
fluid collections in, versus pancreatic pseudocysts, 616–617
function of, 555–559
functional testing of, in chronic pancreatitis, versus endoscopic ultrasonography, 758–759
imaging of, **723–746**. See also *Computed tomography; Magnetic resonance imaging; Ultrasonography.*
magnetic resonance cholangiopancreatography in, 742–743
positron emission tomography in, 743, 745
radionuclide scintigraphy in, 743, 745
infections of, in pancreatitis, antibiotic prophylaxis of, **641–659**
in pseudocysts, 632
inflammation of. See *Pancreatitis.*
injury of, pancreatitis in, 576
innervation of, 553–554
insufficiency of, in cystic fibrosis, 543–544
necrosis of. See *Necrotizing pancreatitis.*
neoplastic cysts of, 617, 622
pseudocysts of. See *Pseudocyst(s), pancreatic.*
retention cysts of, 617
stones in, endoluminal ultrasonography of, 775
endoscopy of, 789–790
ultrasonography of, endoluminal. See *Ultrasonography, of pancreas, endoluminal (intraductal).*
Pancreas divisum, endoscopy in, 769, 785–786
pancreatitis in, 577
Pancreatectomy, in cancer, 717
in pancreatic pseudocyst removal, 629
Pancreatic duct, abnormalities of, pancreatitis in, 577–578, 602, 605
pseudocyst formation in, 618–619
endoscopic drainage through, in pancreatic pseudocyst, 627–628, 788–789
mucinous ectasia of, pancreatitis in, 576
stent in, endoscopic, 791
in cancer palliation, 796
methods for, 788

Pancreatic duct *(Continued)*
pancreatitis from, 575
stones in, endoluminal ultrasonography of, 775
endoscopy of, 789–790
strictures of, endoscopy of, 790–792
ultrasonography within. See *Ultrasonography, of pancreas, endoluminal (intraductal).*
Pancreatic juice, leakage of, pseudocyst formation in, 618
Pancreatic polypeptide, exocrine pancreas interactions with, 554, 559
Pancreatitis, acute, alcohol-induced, 572–574, 621
antibiotic prophylaxis in, **641–659**
biliary, **601–613**
causes of, **571–589**, 602
computed tomography in, 663–664, 738
drug-induced, 575
endoscopic retrograde cholangiopancreatography-induced, 575
endoscopic ultrasonography in, 762
endoscopy in, 783–786
fulminating, 665
genetic factors in, 583–585
hereditary, 583–584
in ampullary stenosis, 578
in anatomic abnormalities, 577
in autoimmune disease, 585
in biliary sludge accumulation, 580–582, 604
in biochemical abnormalities, 576
in cancer, 576
in cystic fibrosis, 584–585
in developmental abnormalities, 577
in gallstone disease. See *Gallstone pancreatitis.*
in hereditary pancreatitis, 526–527
in infections, 585–586
in mucinous duct ectasia, 576–577
in pancreatic duct compression, 578
in sphincter of Oddi dysfunction, 582–583
mortality in, 579, 605–606, 667
necrotizing. See *Necrotizing pancreatitis.*
pathogenesis of, premature trypsin activation in, 533–535
pathophysiology of, 696
sphincterotomy-induced, 575
stent-induced, 575
study timing in, 586–587
toxin-induced, 575
traumatic, 576
treatment of, antibiotic prophylaxis in, **641–659**
medical, **591–599**
surgical, 606–607, **661–671**
alcohol-induced, 572–574
cancer risk in, 674–676
pseudocyst formation in, 621
treatment of, 690
autoimmune, 585
biliary. See *Gallstone pancreatitis.*
cancer risk in, acute, 673–674
chronic, 674–676
hereditary, 527, 676–677
recurrent, 576
tropical, 677
chronic, cancer risk in, **673–685**
cystic fibrosis transmembrane conductance regulator protein defects in, 547–548
endoluminal ultrasonography in, 773
endoscopic ultrasonography in, 755–761
endoscopy in, 786–793
enzymatic treatment of, **687–693**
hereditary, 536
histology of, versus endoscopic ultrasonography, 759–760
in hereditary pancreatitis, 526–527
malabsorption management in, 691–692
nutrition supplementation in, **695–707**
pain management in, 689–691
treatment of, malabsorption management in, 691–692
pain management in, 689–691
common channel theory of, 602
diagnosis of, gallstone, 602–604
necrotizing, 662–663
drug-induced, 575
duration of, infection risk in, 664
endocrine pancreatic disorders in, 561–563
epidemiology of, gallstone, 601
executive, 573–574
gallstone, 134–135. See *Gallstone pancreatitis.*
laparoscopic surgery in, 122–123
hereditary. See *Hereditary pancreatitis.*
idiopathic, endoscopic ultrasonography in, 761–762
investigation of, phase I, 572–576
phase II, 576–578
phase III, 578–586
in cystic fibrosis, **543–550**, 564–565, 584–585
necrotizing. See *Necrotizing pancreatitis.*
pathogenesis of, gallstone, 601–602
platelet-activating factor in, 592–593
trypsinogen activation and, 533–535
postoperative, 576
pseudocyst formation after, 615, 617
recurrent, alcohol-induced, 572–574
causes of, **571–589**
drug-induced, 575

endoscopic retrograde cholangiopancreatography-induced, 575
endoscopy in, 785–786
gallstone, 574–575
genetic factors in, 583–585
hereditary, 583–584
idiopathic, 582
in ampullary stenosis, 578
in anatomic abnormalities, 577
in autoimmune disease, 585
in biliary sludge accumulation, 580–582
in biochemical abnormalities, 576
in cancer, 576
in cystic fibrosis, 584–585
in developmental abnormalities, 577
in infections, 585–586
in mucinous duct ectasia, 576–577
in pancreatic duct compression, 578
in sphincter of Oddi dysfunction, 582–583
mortality in, 579
sphincterotomy-induced, 575
stent-induced, 575
study timing in, 586–587
toxin-induced, 575
traumatic, 576
without sludge, 582
sphincterotomy-induced, 575
stent-induced, 575
toxin-induced, 575
traumatic, 576
tropical, cancer risk in, 677
Pancreatography, ultrasonographic, 765
Pantoprazole, in gastroesophageal reflux disease, 835–836, 849, 869
Parenteral nutrition, in inflammatory bowel disease, 305, 362, 427–430
as primary therapy, 428–429
complications of, 427–428
in pediatric patients, 455
preoperative, 428
refractory, 362
Pediatric patients, Barrett's esophagus in, 951–952
esophageal adenocarcinoma in, 952
gastroesophageal reflux disease in, **947–969**
clinical features of, 948–949
complications of, 950–952
course of, 950–952
diagnosis of, 955–961
differential diagnosis of, 956
pathophysiology of, 952–955
physiologic, 948–950
prevalence of, 947
spectrum of, 948
treatment of, 961–965
versus adults, 950
inflammatory bowel disease in, 275, **445–458**
clinical features of, 446–447
diagnosis of, 451–453
differential diagnosis of, 453
epidemiology of, 445–446
extraintestinal manifestations of, 449–450
gastrointestinal complications of, 447–449
growth failure in, 451
treatment of, 453–456
laparoscopic biliary surgery in, 123
peptic stricture in, 951
Pefloxacin, prophylactic, in pancreatitis, 649, 651–652
Peptic strictures, esophageal. See *Esophagus, peptic strictures of.*
Percutaneous drainage, of pancreatic pseudocyst, 626–627, 630
Perianal Crohn's disease, in pediatric patients, 449
treatment of, 363
Pericholangitis, in inflammatory bowel disease, 506
Peristalsis, esophageal, in gastroesophageal reflux disease, 905–907
Peritonitis, in Crohn's disease, treatment of, 360
in ruptured pancreatic pseudocyst, 632
Peroxisomal disorders, bile acid synthesis defects, 164–165
PFIC1 gene, in Blyler's syndromes, 44–45
PFIC2 gene, in Blyler's syndromes, 45
pH monitoring, in gastroesophageal reflux disease, 814–817, 853–854
in pediatric patients, 958–959
preoperative, 994
Phosphodiesterase inhibitors, in inflammatory bowel disease, 331
Phospholipids, in bile. See *Biliary lipids.*
Photodynamic therapy, for Barrett's esophagus, 920
Pigment gallstones, composition of, 76
formation of, 105–107
black, 88
brown, 89–91
Piperacillin, prophylactic, in pancreatitis, 648–649, 657
Platelet-activating factor, in pancreatitis pathogenesis, 592–593
Pneumocolon, peroral, with small bowel enema, in inflammatory bowel disease, 392–393
Pneumonia, in gastroesophageal reflux disease, 949–950
Pneumoperitoneum, in laparoscopic biliary surgery, 118
Polymyxin B, in selective gut decontamination, in pancreatitis, 654
Polyps, gallbladder, laparoscopic surgery for, 124–125

Porcelain gallbladder, cancer risk in, 135
prophylactic cholecystectomy in, 118
Portal triaditis (pericholangitis), in inflammatory bowel disease, 506
Positioning, in gastroesophageal reflux disease, 961–962
Positron emission tomography, of pancreas, 743, 745
Postcholecystectomy syndrome, 137
Posttransplant lymphoproliferative disorder, 235, 240
Postural therapy, for gastroesophageal reflux disease, 961–962
Pouchitis, after ileoanal anastomosis, 380–382
Prednisolone, in inflammatory bowel disease, 355
Prednisone, in collagenous colitis, 485
in inflammatory bowel disease, 300–301
distal, 354
for remission maintenance, 360
Pregnancy, gallstone formation in, 86
laparoscopic biliary surgery in, 123–124
Primary biliary cirrhosis, 174–183
diagnosis of, 174
incidence of, 174
pathogenesis of, 174
treatment of, 174–175
ursodeoxycholic acid in, 175–183, 203
Primary sclerosing cholangitis, bile acid abnormalities in, 182, 184–187
in inflammatory bowel disease, 268–269, 492–505
cancer risk and, 463–464
classification of, 492
clinical features of, 496–497
complications of, 502–505
definition of, 492
diagnosis of, 496–499
diseases associated with, 493
epidemiology of, 492–493
etiopathogenesis of, 493–496
genetic factors in, 495
histopathology of, 499
in pediatric patients, 450
laboratory findings in, 497–498
natural history of, 492, 497
radiology in, 498–499
treatment of, 499–505
Probiotic therapy, for inflammatory bowel disease, 325
Proctitis, ulcerative, treatment of, 353–354
Proctocolectomy, in Crohn's disease, 386–388
in ulcerative colitis, with ileostomy, 374
Proctocolitis, in Crohn's disease, surgical treatment of, 386–388
Proliferative markers, for Barrett's esophagus malignant degeneration, 937–938
Promotility agents, in gastroesophageal reflux disease, 837–839
Protease preparation, in chronic pancreatitis, 690–691
Protective effects, on liver function. See *Hepatoprotective effects.*
Protein requirements, in inflammatory bowel disease, 426
Proton-pump inhibitors. See also specific drugs, e.g., *Omeprazole.*
in esophageal peptic stricture, 884–885
in gastroesophageal reflux disease, 849–853, 990–991
Helicobacter pylori and, 977–978
in pediatric patients, 964
Provocative testing, in gastroesophageal reflux disease, 818
Pseudoaneurysm, pancreatic, 632–633
Pseudocyst(s), pancreatic, **615–639**
acute, 617
causes of, 621, 624
chronic, 617
clinical features of, 621
complications of, 631–634
definition of, 615–617
diagnosis of, 622–623
differential diagnosis of, 617
drainage of, 625–631, 788–789
endoscopic ultrasonography in, 754–755
endoscopy in, 787–789
epidemiology of, 616
multiplicity of, 619, 624
natural history of, 623–625
pathogenesis of, 618–619
pathology of, 619–620
postnecrotic, 617
size of, 623–624
somatostatin treatment of, 631
Psychologic factors, in endoscopy-negative gastroesophageal reflux disease, 898–899
Pulmonary fibrosis, idiopathic, gastroesophageal reflux disease and, 867
Pulmonary manifestations, of gastroesophageal reflux disease, 813, 820, 822
in pediatric patients, 949–950
treatment of, 1009–1010
Pyoderma gangrenosum, in inflammatory bowel disease, 449

Quality of life, in inflammatory bowel disease, 270, 274–275

Rabeprazole, in gastroesophageal reflux disease, 835–837, 849, 869

Racial factors, in Barrett's esophagus malignant degeneration, 923
in inflammatory bowel disease, 259
in pancreatic cancer, 680–681
Radiation therapy, for pancreatic cancer, 718–719
Radionuclide scintigraphy, in gastroesophageal reflux disease, 817–818, 960
of pancreas, 743, 745
Ranitidine, in esophageal peptic stricture, 885
in gastroesophageal reflux disease, 834–835, 839–840
endoscopy-negative, 900
in pediatric patients, 964
refractory, 855–856
Ranson's criteria, for pancreatitis classification, 605
Red blood cells, membranes of, ursodeoxycholic acid effects on, 201–202
Refeeding, in pancreatitis, 701
Reflexes, esophageal, gastroesophageal reflux disease and, 862
Reflux, esophageal. See *Gastroesophageal reflux disease.*
Regurgitation, in Barrett's esophagus, 921
in gastroesophageal reflux disease, 811, 948
Relaxation training, in gastroesophageal reflux disease, 832
Remnants, chylomicron, 215
Respiratory system, gastroesophageal reflux disease manifestations in, 813, 820, 822
in pediatric patients, 949–950
treatment of, 1009–1010
Reverse cholesterol transport, 8, 15, 219
Ridogrel, in inflammatory bowel disease, 337–338
Rifampin, in inflammatory bowel disease, in cholestasis, 502
Rings, esophageal, peptic stricture in, 879
Ropivacaine, in inflammatory bowel disease, 336
Rosetti modification, of Nissen fundoplication, 1011
Roux-en-Y loop surgery, in peptic stricture, 888

Sacroiliitis, in inflammatory bowel disease, 268
Savary-Gilliard dilators, in peptic stricture, 886–887
Schatzki's ring, peptic stricture in, 879
Scintigraphy, in gastroesophageal reflux disease, 817–818, 960
of pancreas, 743, 745
Scleroderma, Barrett's esophagus malignant degeneration and, 932–933
esophageal peptic stricture in, 879
Sclerosing cholangitis, primary. See *Primary sclerosing cholangitis.*
Selective gut decontamination, in pancreatitis, 652–654
Shock-wave lithotripsy, extracorporeal, for gallstone dissolution, 138–139
Simethicone, in gastroesophageal reflux disease, 833
Sister of P glycoprotein, in bile acid transport, 39, 62, 80
Skin lesions, in inflammatory bowel disease, 268, 449
squamous cell carcinoma, 472–473
Sludge, biliary, gallstone formation and, 84, 109
pancreatitis in, 580–582, 604
Small intestine, adenocarcinoma of, in inflammatory bowel disease, 472
enema of, with peroral pneumocolon, in inflammatory bowel disease, 392–393
obstruction of, in Crohn's disease, 360
pancreatic interactions with, 554–559
Smith-Lemli-Opitz syndrome, 161–162
Smoking, disease risks in, in Barrett's esophagus malignant degeneration, 926–928
inflammatory bowel disease, 262–263
pancreatic cancer, 679–680
Socioeconomic factors, in Barrett's esophagus malignant degeneration, 923–926
in inflammatory bowel disease, 260
Sodium-dependent bile acid transporters, 33–34
Solvents, for gallstone dissolution, 139–140
Somatostatin, exocrine pancreas interactions with, 554, 558
in inflammatory bowel disease, 335
in pancreatic pseudocyst, 631
secretion of, 553
Sphincter of Oddi dysfunction, endoscopy in, 785
pancreatitis in, 582–583
Sphincterotomy, endoscopic, in chronic pancreatitis, 787
in pancreas divisum, 785–786
in sphincter of Oddi dysfunction, 785
in pancreatitis, endoscopic, 787
pancreatitis after, 575
Spinal cord injury, gallstone formation and, 88
Squamous cell carcinoma, of skin, in inflammatory bowel disease, 472–473
Staging, of pancreatic cancer, 713–716, 749–751, 795

Steatorrhea, in ileal resection or dysfunction, 12
in pancreatitis, management of, 691–692, 701–704
Stent placement, in pancreatic duct, endoscopic, 791
in cancer palliation, 796
methods for, 788
pancreatitis after, 575
Sterol 12α-hydroxylase, in bile acid synthesis, 16–17
Sterol 27-hydroxylase, deficiency of, 18
in bile acid synthesis, 6, 15–16
Stomach, dysfunction of, gastroesophageal reflux disease in, 988–989
Stones, gallbladder. See *Gallstones.*
kidney, in inflammatory bowel disease, 450
pancreatic duct, endoluminal ultrasonography of, 775
endoscopy of, 789–790
Stress, in endoscopy-negative gastroesophageal reflux disease, 898–899
Strictureplasty, in Crohn's disease, 384–386
Strictures, peptic, of esophagus. See *Esophagus, peptic strictures of.*
Stridor, in gastroesophageal reflux disease, 949
Subglottic stenosis, in gastroesophageal reflux disease, 867–869
Substance P, in inflammatory bowel disease, 335–336
Sulfasalazine, in collagenous colitis, 485
in inflammatory bowel disease, 297–299
distal, 354
ileal, 359
in pediatric patients, 454
left-sided, 355
Superoxide dismutase, in inflammatory bowel disease, 338
Symptom index correlation, in esophageal pH monitoring, 815–816, 864

T lymphocytes, helper, in inflammatory bowel disease treatment, 326
in inflammatory bowel disease pathogenesis, 287–288
Tacrolimus, gastrointestinal complications of, 234, 236–237
in inflammatory bowel disease, 306, 334
Taurohydrodeoxycholic acid, hepatoprotective effects of, 204
Thalidomide, in inflammatory bowel disease, 331
Therapeutic trial, in gastroesophageal reflux disease, 818–820
Throat disorders, in gastroesophageal reflux disease, 867–869
in pediatric patients, 949
Thromboembolic disease, of inflammatory bowel disease, 450
Thyroid hormone, in cholesterol 7α-hydroxylase feedback regulation, 13–14
Tobacco use, disease risks in, in Barrett's esophagus malignant degeneration, 926–928
inflammatory bowel disease, 262–263
pancreatic cancer, 679–680
Tobramycin, in inflammatory bowel disease, 325
Topical dissolution therapy, for gallstones, 139–140
Toupet fundoplication, in gastroesophageal reflux disease, 996
Toxic megacolon, in inflammatory bowel disease, 373–374, 448
Toxins, pancreatitis due to, 575
TPN. See *Parenteral nutrition.*
Transenteric drainage, of pancreatic pseudocyst, 628–629
Transpapillary drainage, of pancreatic pseudocyst, 627–628, 788
Transplantation, immunosuppressive agents in. See *Immunosuppressive agents.*
liver, in primary sclerosing cholangitis, 505
Trauma, pancreatitis in, 576
Triamcinolone, intralesional, in esophageal peptic stricture, 886
Tropical pancreatitis, cancer risk in, 677
Trypsin, action of, 530–531, 552, 689
inhibitors of, 533
formation of, 552
premature activation of, mechanisms of, 533–535
protection against, 533
structure of, 530–531
Trypsinogen mutations, in hereditary pancreatitis, 528–536
acute pancreatitis initiation in, 533
mechanistic hypothesis of, 530–533
trypsin activation protection and, 533
Tumor markers, for Barrett's esophagus malignant degeneration, 937–938
for pancreatic cancer, 712–713
Tumor necrosis factor, in pancreatitis pathogenesis, 592–593
Tumor necrosis factor-α, antibodies to, in inflammatory bowel disease, 329–330, 362
in inflammatory bowel disease treatment, 326–327
inhibitors of, in inflammatory bowel disease treatment, 331
Tumor-associated islet cells, 563
Tumor-suppressor genes, mutations of, in Barrett's esophagus malignant degeneration, 934–937

Ulcerative colitis, age of onset of, cancer risk and, 463
cancer in, 269, 459–469
biology of, 459–460
hematologic, 471–472
prevention of, 464–469
risk for, 460–464
surgical prophylaxis of, 372, 464–465
surveillance for, 465–468
clinical features of, in pediatric patients, 446–447
complications of, 266–269
diagnosis of, 451–453
differential diagnosis of, 453
distal, treatment of, 354
distribution of, radiography of, 394–395
duration of, cancer risk and, 461
emergencies in, surgical treatment of, 373–374
endoscopy in. See *Endoscopy, in inflammatory bowel disease.*
epidemiology of, 255–260
in pediatric patients, 445–446
extent of, cancer risk and, 461, 463
extraintestinal manifestations of, 267–269
in pediatric patients, 449–450
surgical treatment for, 372
fulminant, treatment of, 355–356
gastrointestinal complications of, 447–449
genetic factors in, 260–262, 284–285
hepatobiliary disease in. See *Hepatobiliary disease, in inflammatory bowel disease; Primary sclerosing cholangitis.*
cancer risk and, 463–464
heterogeneity of, 285
in elderly persons, 275–276
in pediatric patients. See *Pediatric patients, inflammatory bowel disease in.*
in proctitis, treatment of, 353–354
left-sided, treatment of, 354–355
natural history of, 265–270
nutrition in. See *Nutrition, in inflammatory bowel disease.*
pancolitis, treatment of, 354–355
pathogenesis of, **283–296**
animal models of, 288–290
environmental factors in, 262–264, 284–285
genetic factors in, 260–262
theories on, 286–288
quality of life in, 270
radiography in, barium enema in, 393–394
computed tomography in, 394
findings in, 396–402
in disease distribution, 394, 396
peroral pneumocolon with small bowel enema in, 392–393
plain film in, 392
refractory, surgical treatment of, 371–372
risk factors for, 260–265
severe, treatment of, 355–356
severity of, 265
steroid-dependent, treatment of, 357–358
steroid-refractory, treatment of, 356–357
survival in, 269–270
treatment of, adhesion molecule inhibitors in, 336–337
aminosalicylates in. See *5-Aminosalicylates.*
anesthetics in, 336
antibiotics in, 304–305, 324–325
antigen-directed, 323–325
arachidonic acid metabolites in, 337–338
biologic approaches to, 307
bismuth subsalicylate in, 340
cancer risk and, 464
chloroquine in, 340
clinical presentation and, 353–358
corticosteroids in. See *Corticosteroids.*
cytokines in, anti-inflammatory, 332–334
proinflammatory, 325–331
distal, 354
free radical inhibitors in, 338
fulminant, 355–356
heparin in, 340
immunoglobulins in, 341
immunomodulators in, 301–304
immunosuppressive agents in, 334
immunotherapy in, 290–291
in pediatric patients, 453–456
in proctitis, 353–354
interferon-α in, 340
investigational therapies in, 307
ketotifen in, 340
left-sided, 354–355
leukapheresis in, 341
medical, **297–321**
cancer risk and, 464
in pediatric patients, 454–455
neuroimmunomodulators in, 334–336
nicotine in, 307, 339, 357
novel, **323–351**
nutritional therapy in. See *Nutrition, in inflammatory bowel disease.*
pancolitis, 354–355
probiotics in, 325
severe, 355–356
short-chain fatty acids in, 338–339
steroid-dependent, 357–358
steroid-refractory, 356–357
supportive therapy in, 305–306
surgical, 371–383
continent ileostomy in, 375–376
emergency, 373–374
ileoanal anastomosis in, 376–383
in cancer prevention, 464–465

Ulcerative colitis *(Continued)*
indications for, 371–372
proctocolectomy with ileostomy in, 374
subtotal colectomy in, 374–375
versus collagenous colitis, 481
versus diversion colitis, 488
Ultrasonography, endoscopic, in inflammatory bowel disease, 418
of pancreas, endoluminal (intraductal), 743, 763–764, **771–781**
complications of, 779
in cancer, 773, 776, 788–789
in chronic pancreatitis, 773
in cystic tumors, 776–777
in stone disease, 775
methods for, 771–772
normal results of, 774
uses of, 779–780
endoscopic, 743, **747–770**
in acute pancreatitis, 762
in anatomic anomalies, 764
in cancer, 715, 747–753, 788
in chronic pancreatitis, 755–761, 786
in cysts, 754–755
in endocrine tumors, 753–754
in fine-needle aspiration, 751–753, 764–765
in idiopathic pancreatitis, 761–762
in pancreas divisum, 786
in pseudocysts, 754–755
in staging, 749–751
interventional, 764–766
in pseudocyst, 622
Urologic manifestations, of inflammatory bowel disease, 450
Ursodeoxycholic acid, hepatoprotective effects of, antioxidant, 203
immunomodulatory, 203–204
in cholestasis, animal studies of, 200
bile flow increase, 198–200
estrogen-induced, 200–201
secretory improvement, 198–200
toxic bile acid displacement, 197–198
in hepatocyte culture, 201
on membranes, 201–203
on mitochondria, 201–203
therapeutic, in cholestasis, familial intrahepatic, 71–72
hepatoprotective effects of, 197–201
in Blyler's disease, 188
in Caroli's syndrome, 188
in cystic fibrosis, 186
in gallstone dissolution, 138
with lithotripsy, 139
in lipid-lowering, 224–225
in 3-oxosteroid 5β-reductase deficiency, 155
in primary biliary cirrhosis, 175–183, 203
bile acid effects of, 176–180, 183
bile alcohol effects of, 179, 181
clinical effects of, 175–176
mechanism of action of, 181–182
in primary sclerosing cholangitis, 184–187
Uveitis, in inflammatory bowel disease, 268, 449

VacA protein, of *Helicobacter pylori*, gastroesophageal reflux and, 976
Vapreotide, in inflammatory bowel disease, 335
Vesicles, in bile acid transport, 37
Viokase pancreatic enzyme preparation, in chronic pancreatitis, 690
Viral infections, from immunosuppressive agents, 239–241
Vitamins, deficiencies of, in inflammatory bowel disease, 424
in nutritional supplementation, for pancreatitis, 700–701
Vocal cord nodules, in gastroesophageal reflux disease, 867–869
Vomiting, after antireflux surgery, 1015–1016
from immunosuppressive agents, 242

Weight loss, rapid, gallstone formation and, 86
Whipple procedure, in pancreatic cancer, 717

Xanthomatosis, cerebrotendinous, in bile acid synthesis defects, 18, 162

Zellweger's syndrome, 164–165
Zinc deficiency, in inflammatory bowel disease, 424
Zollinger-Ellison syndrome, esophageal peptic stricture in, 876–877
treatment of, proton-pump inhibitors in, 851